Table of Contents Author Guidelines Submit a Manuscript
Genetics Research International
Volume 2017 (2017), Article ID 6293826, 5 pages
https://doi.org/10.1155/2017/6293826
Research Article

Genetic Variants in CSMD1 Gene Are Associated with Cognitive Performance in Normal Elderly Population

1Institute of Medical Genetics, Tomsk National Medical Research Center, Tomsk, Russia
2Tomsk State University, Tomsk, Russia
3Nebbiolo Center for Clinical Trials, Tomsk, Russia

Correspondence should be addressed to Vadim Stepanov; ur.scitenegdem@vonapets.midav

Received 1 October 2017; Accepted 22 November 2017; Published 12 December 2017

Academic Editor: Chao Zhao

Copyright © 2017 Vadim Stepanov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Kraus, G. S. Elliott, H. Chute et al., “CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues,” The Journal of Immunology, vol. 176, no. 7, pp. 4419–4430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. V. M. Steen, C. Nepal, K. M. Ersland et al., “Neuropsychological deficits in mice depleted of the schizophrenia susceptibility gene CSMD1,” PLoS ONE, vol. 8, no. 11, Article ID e79501, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, “Genome-wide association study identifies five new schizophrenia loci,” Nature Medicine, vol. 18, no. 43, pp. 969–976, 2011. View at Publisher · View at Google Scholar
  4. Cross-Disorder Group of the Psychiatric Genomics Consortium, “Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis,” The Lancet, vol. 381, no. 9875, pp. 1371–1379, 2013. View at Publisher · View at Google Scholar
  5. Schizophrenia Working Group of the Psychiatric Genomics Consortium, “Biological insights from 108 schizophrenia-associated genetic loci,” Nature, vol. 511, pp. 421–427, 2014. View at Google Scholar
  6. F. S. Goes, J. Mcgrath, D. Avramopoulos et al., “Genome-wide association study of schizophrenia in Ashkenazi Jews,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 168, no. 8, pp. 649–659, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Donohoe, J. Walters, A. Hargreaves et al., “Neuropsychological effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253,” Genes, Brain and Behavior, vol. 12, no. 2, pp. 203–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Koiliari, P. Roussos, E. Pasparakis et al., “The CSMD1 genome-wide associated schizophrenia risk variant rs10503253 affects general cognitive ability and executive function in healthy males,” Schizophrenia Research, vol. 154, no. 1-3, pp. 42–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. E. T. Cirulli, D. Kasperavičiũt, D. K. Attix et al., “Common genetic variation and performance on standardized cognitive tests,” European Journal of Human Genetics, vol. 18, no. 7, pp. 815–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. V. A. Stepanov, A. V. Bocharova, A. V. Marusin, N. G. Zhukova, V. M. Alifirova, and I. A. Zhukova, “Replicative association analysis of genetic markers of cognitive traits with Alzheimer’s disease in the Russian population,” Journal of Molecular Biology, vol. 48, no. 6, pp. 835–844, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. V. Bocharova, V. A. Stepanov, A. V. Marusin et al., “Association study of genetic markers of schizophrenia and its cognitive endophenotypes,” Russian Journal of Genetics, vol. 53, no. 1, pp. 139–146, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Hayden, O. A. Makeeva, L. K. Newby et al., “A comparison of neuropsychological performance between US and Russia: preparing for a global clinical trial,” Alzheimer’s & Dementia, vol. 10, no. 6, pp. 760–768, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. O. A. Makeeva, H. R. Romero, V. V. Markova et al., “Vascular risk factors confer domain-specific deficits in cognitive performance within an elderly russian population,” Alzheimer's & Dementia, vol. 11, no. 7, pp. P894–P895, 2015. View at Publisher · View at Google Scholar
  14. V. A. Stepanov and E. A. Trifonova, “Multiplex genotyping of single nucleotide polymorphisms by MALDI-TOF mass-spectrometry: ferequencies of 56 SNP in immune response genes in human populations,” Molekularna Biologija, vol. 47, no. 6, pp. 976–986, 2013. View at Google Scholar · View at Scopus
  15. K. Ohi, R. Hashimoto, H. Yamamori et al., “The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia,” Behavioral and Brain Functions, vol. 9, no. 1, article 40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, Z. Cheng, J. Wang et al., “No association between the rs10503253 polymorphism in the CSMD1 gene and schizophrenia in a Han Chinese population,” BMC Psychiatry, vol. 16, no. 1, article 206, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Athanasiu, S. Giddaluru, C. Fernandes et al., “A genetic association study of CSMD1 and CSMD2 with cognitive function,” Brain, Behavior, and Immunity, vol. 61, pp. 209–216, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. V. A. Stepanov, A. V. Bocharova, K. Z. Saduakassova et al., “Replicative study of susceptibility to childhood-onset schizophrenia in Kazakhs,” Russian Journal of Genetics, vol. 51, no. 2, pp. 185–192, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Sherva, Y. Tripodis, D. A. Bennett et al., “Genome-wide association study of the rate of cognitive decline in Alzheimer's disease,” Alzheimer’s & Dementia, vol. 10, no. 1, pp. 45–52, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Sakamoto, M. Takaki, Y. Okahisa et al., “Individual risk alleles of susceptibility to schizophrenia are associated with poor clinical and social outcomes,” Journal of Human Genetics, vol. 61, no. 4, pp. 329–334, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. E. J. Rose and G. Donohoe, “Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia,” Schizophrenia Bulletin, vol. 39, no. 3, pp. 518–526, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. E. J. Rose, D. W. Morris, A. Hargreaves et al., “Neural effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 162, no. 6, pp. 530–537, 2013. View at Publisher · View at Google Scholar · View at Scopus